239 related articles for article (PubMed ID: 7527671)
1. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
3. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
[TBL] [Abstract][Full Text] [Related]
4. YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.
Wu CC; Kuo SC; Lee FY; Teng CM
Eur J Pharmacol; 1999 Sep; 381(2-3):185-91. PubMed ID: 10554886
[TBL] [Abstract][Full Text] [Related]
5. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
7. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Teng CM; Wu CC; Ko FN; Lee FY; Kuo SC
Eur J Pharmacol; 1997 Feb; 320(2-3):161-6. PubMed ID: 9059849
[TBL] [Abstract][Full Text] [Related]
8. Effect of PP1D-1, a synthetic antiplatelet compound, on rabbit platelets.
Liao CH; Ko FN; Kuo SC; Teng CM
Jpn J Pharmacol; 1998 Feb; 76(2):141-8. PubMed ID: 9541276
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet function by A02131-1, a novel inhibitor of cGMP-specific phosphodiesterase, in vitro and in vivo.
Yu SM; Tsai SY; Kuo SC; Ou JT
Blood; 1996 May; 87(9):3758-67. PubMed ID: 8611701
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of demethyldiisoeugenol.
Liao CH; Ko FN; Kuo YH; Teng CM
Can J Physiol Pharmacol; 1996 Oct; 74(10):1111-6. PubMed ID: 9022830
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
13. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound.
Ding YA; Chou TC; Chern JW; Yen MH
Thromb Res; 1995 Feb; 77(3):291-303. PubMed ID: 7740521
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
16. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets.
Lin CH; Kuo SC; Huang LJ; Huang TF; Teng CM
Thromb Res; 1992 Apr; 66(1):61-73. PubMed ID: 1412184
[TBL] [Abstract][Full Text] [Related]
17. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
18. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
19. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of collagen-induced platelet aggregation and adhesion by a pseudocyanide derivative of avicine isolated from Zanthoxylum integrifoliolum Merr.
Ko FN; Hsiao G; Chen IS; Wu SJ; Teng CM
Biochem Pharmacol; 1993 Oct; 46(7):1165-73. PubMed ID: 8216367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
